Study of the Safety & PK of INX-08189 in Chronically-infected HCV, Treatment-naïve Subjects

This is a multi-center, sequential-cohort, double-blind, placebo-controlled, multiple
ascending dose, 7-day treatment study in chronically-infected genotype 1 HCV,
treatment-naïve subjects.

Primary Objectives include:

Safety

• to evaluate the safety of ascending oral doses of INX-08189 given once a day for seven (7)
days in chronically-infected genotype 1 HCV, treatment-naïve subjects

Pharmacokinetic

• to characterize the pharmacokinetic (PK) profile of multiple ascending oral doses of
INX-08189 in chronically-infected genotype 1 HCV, treatment-naïve subjects

Pharmacodynamic

• to evaluate the relationship between the metrics of the reduction from baseline in serum
HCV RNA and PK parameters of INX-08189 and the metabolite INX-08032

Efficacy

• to measure the maximal reduction in plasma HCV RNA by ascending oral dose level of
INX-08189 given once a day for seven (7) days in chronically-infected genotype 1 HCV,
treatment-naïve subjects